• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    New HIV and Breast Cancer Wins Might Change The Case For Investing In Gilead Sciences (GILD)

    Simply Wall St·08/31/2026 08:14:18
    Listen to the news
    • In late August 2026, Gilead Sciences secured FDA approval for Bixlenvo, a once-daily single-tablet HIV regimen for virologically suppressed adults, and European Commission authorization for Trodelvy plus Keytruda as a first-line treatment for PD-L1–positive metastatic triple-negative breast cancer.
    • These approvals extend Gilead’s reach in both HIV and oncology care, reinforcing its role in simplifying complex HIV regimens and establishing Trodelvy-based combinations as a cornerstone option in difficult-to-treat breast cancer across Europe.
    • We’ll now examine how Bixlenvo’s once-daily HIV regimen shapes Gilead’s existing investment narrative around pipeline expansion and portfolio diversification.

    Outshine the giants: these 18 early-stage AI stocks could fund your retirement.

    Gilead Sciences Investment Narrative Recap

    To own Gilead today, you need to believe that its HIV leadership and growing oncology franchise can offset pricing pressure and execution risk in new launches. The Bixlenvo and Trodelvy updates support the near term diversification catalyst but do not materially change the biggest current risk around HIV pricing and future patent cliffs.

    Among the latest announcements, the EU approval of Trodelvy plus Keytruda in first line PD L1 positive metastatic triple negative breast cancer stands out. It deepens Gilead’s oncology footprint at the same time Bixlenvo refines its HIV portfolio, which together speak directly to the core catalyst of pipeline driven diversification that consensus expectations already build into future revenue and margin forecasts.

    Yet even with these advances, investors still need to weigh the growing policy and pricing risks that could...

    Read the full narrative on Gilead Sciences (it's free!)

    Gilead Sciences' narrative projects $34.5 billion revenue and $10.8 billion earnings by 2029.

    Uncover how Gilead Sciences' forecasts yield a $157.83 fair value, a 8% upside to its current price.

    Exploring Other Perspectives

    GILD 1-Year Stock Price Chart
    GILD 1-Year Stock Price Chart

    Before this news, the most optimistic analysts were banking on revenue reaching about US$38.1 billion and earnings of roughly US$12.7 billion by 2029, which is far more upbeat than the consensus view and assumes launches like Trodelvy expansions will hit full stride despite the risk that new products may not achieve the uptake or reimbursement those forecasts require.

    Explore 5 other fair value estimates on Gilead Sciences - why the stock might be worth 12% less than the current price!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Looking For Alternative Opportunities?

    Our top stock finds are flying under the radar-for now. Get in early:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.